Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Empower your strategies with our Uremic (Renal) Pruritus – Drugs In Development, 2024 report and make more profitable business decisions.

Uremic pruritis is a condition where there is presence of excess urea in the blood associated with itchiness (pruritis). It is associated with chronic kidney disease (CKD). Most common in end stage CKD and patients on hemodialysis. Underlying diseases (CKD), diabetes, inflammation, uremic toxins are common triggering factors affecting 20-25% of body surface area and is associated with itchiness, secondary skin changes like eczema, lichen simplex, dry skin, triggered when exposed to sun, radiation etc. Diagnosed by skin biopsy, blood and urine analysis to find out the levels of urea, GFR rate, and differential diagnosis. Topical therapies like topical analgesics, emollients, tacrolimus to suppress the production of interleukins, antihistamines to treat itchiness, opioid agonist and antagonist, phototherapy and in complicated cases renal transplantation chosen.

The Uremic (Renal) Pruritus drugs in development market research report provide comprehensive information on the therapeutics under development for Uremic (Renal) Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uremic (Renal) Pruritus and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope of Report

  • Therapeutics in Development: Covering 10 molecules, with 10 developed by companies and the rest by universities/institutes.
  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
  • Development History: Access the complete research and development history.
  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to buy

  • Holistic insights: Understand the broad spectrum of Uremic (Renal) Pruritus therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
  • Pipeline Exploration: Explore the detailed Uremic (Renal) Pruritus pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Uremic (Renal) Pruritus treatments for adaptable decision-making.
  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

What our clients have to say

More Reports

View More Reports